Source: No information given
Area: News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the adoption of two new contraindications for Ozurdex® (dexamethasone intravitreal implant), as follows:
. Aphakic eyes with rupture of the posterior lens capsule; . Eyes with Anterior Chamber Intraocular Lens (ACIOL) and rupture of the posterior lens capsule
Detailed conditions for the use of this product will be described in the updated summary of product characteristics, which will be published in the revised (Read more...)
Uncategorized